Director of Biopharma Partnerships

• Unilabs is one of Europe's leading diagnostics groups—processing over 237 million diagnostic tests annually
• across 14 countries. Unilabs.AI (ULAI) is a standalone, seed-stage company venture-backed by Unilabs and A.P.
• Møller Holding, built to turn this massive legacy infrastructure into a structured, queryable, real-time clinical data
• asset.

Core Responsibilities

1. The Hunt: Origination & Pipeline Building

• Targeted Prospecting: Systematically map the global Biopharma landscape (especially in Rare Diseases,

• Targeted Oncology, and Immunology) to identify active Phase 2b/3 pipelines that are bottlenecked by patient
• recruitment.

• Evangelizing the ULAI Dragnet: Secure high-level meetings with VPs of Clinical Operations, Heads of RWD,

• and Clinical Development Leaders. Pitch the unique value of our multi-modal OS infrastructure and prove how
• we can intercept their exact inclusion/exclusion criteria upstream.

• Network Leverage: Utilize your existing rolodex within Biopharma to fast-track conversations, bypassing

• standard procurement layers to engage directly with the clinical decision-makers feeling the pain of delayed
• trials.

1. Complex Deal Execution

• Solution Architecture: Work with Pharma sponsors to define the exact diagnostic footprint required (e.g.,

• combining imaging findings with declining kidney function for rare disease profiles) and translate that into a
• commercial data/recruitment contract.

• Closing: Own the end-to-end sales cycle. Negotiate complex SaaS, RWD licensing, and milestone-based

clinical recruitment contracts from initial MSA through to final signature.

1. Alliance Management & Delivery

• The Clinical Bridge: You don't just sell the deal and walk away. You will serve as the Alliance Manager, bridging

• the gap between the Pharma sponsor's clinical teams and ULAI’s internal engineering and clinical informatics
• teams.

• Execution Oversight: Ensure that the data pipelines and screening algorithms we deploy actually yield the

patient volumes and RWD quality promised in the contract.

• Account Expansion: Once a pilot rare disease dragnet proves successful, leverage that internal Pharma

champion to expand ULAI's contracts across their broader therapeutic portfolio.

Requirements

• The Hunter Mentality: You are deeply uncomfortable with an empty calendar. You are relentless, resilient, and

view pipeline generation as the most critical part of your day.

• Domain Fluency: You speak the language of clinical trials, real-world evidence, and targeted therapeutics. You

• understand what Phase 2a vs. Phase 3 requires, what a synthetic control arm is, and why recruiting for a rare
• genetic disease is a nightmare.

• Track Record: 5–10+ years of quota-carrying BD experience selling RWD, complex CRO services, genomic

• testing, or tech-enabled clinical trial solutions directly to Biopharma. You have a documented history of closing
• complex, large-scale deals.

• Autonomy & Grit: You thrive in a seed-stage, fast-moving environment. You do not need a massive marketing

department to generate a pitch deck; you build the narrative, find the target, and close the deal.

• Language: Fluent English is mandatory; professional proficiency in French or German is highly advantageous.

Benefits

• Hybrid working model (office & remote flexibility)
• International, collaborative, and regulated product environment
• Competitive compensation and benefits
• Long-term ownership of a strategic healthcare product
• Unmatched Product-Market Fit: You are selling access to Europe's largest, highly protected, multi-modal

diagnostic pool—a proprietary asset that no standard software company or CRO can replicate.

• True Entrepreneurial Ownership: The execution speed and equity upside of a venture-backed

standalone startup, powered by the operational footprint of Unilabs and A.P. Møller Holding.